Clinical significance of early circulating tumor cells (CTC) changes, analyzed by AdnaTest, in patients (pts) receiving first-line methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy (CT) for metastatic urothelial cancer (UC)

Necchi A.; Fina E.; Giannatempo P.; Colecchia M.; Raggi D.; Daidone M. G.; Cappelletti V.

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Clinical significance of early circulating tumor cells (CTC) changes, analyzed by AdnaTest, in patients (pts) receiving first-line methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy (CT) for metastatic urothelial cancer (UC)

【24h】

Clinical significance of early circulating tumor cells (CTC) changes, analyzed by AdnaTest, in patients (pts) receiving first-line methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy (CT) for metastatic urothelial cancer (UC)

机译：早期循环肿瘤细胞（CTC）变化的临床意义，通过Adnatest，在患者（PTS）接受一线甲氨蝶呤，长春细胞，多柔比星和顺铂（MVAC）化疗（CT）进行转移性尿路上皮癌（UC）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2016年第null期|共2页
作者
Necchi A.; Fina E.; Giannatempo P.; Colecchia M.; Raggi D.; Daidone M. G.; Cappelletti V.;
展开▼
作者单位

Fdn IRCCS Ist Nazl Tumori Med Oncol Milan Italy;

Fdn IRCCS Ist Nazl Tumori Expt Oncol &

Mol Med Milan Italy;

Fdn IRCCS Ist Nazl Tumori Med Oncol Milan Italy;

Fdn IRCCS Ist Nazl Tumori Pathol Milan Italy;

Fdn IRCCS Ist Nazl Tumori Med Oncol Milan Italy;

Fdn IRCCS Ist Nazl Tumori Expt Oncol &

Mol Med Milan Italy;

Fdn IRCCS Ist Nazl Tumori Expt Oncol &

Mol Med Milan Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Clinical significance of early circulating tumor cells (CTC) changes, analyzed by AdnaTest, in patients (pts) receiving first-line methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy (CT) for metastatic urothelial cancer (UC) [J] . Necchi A., Fina E., Giannatempo P., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：通过AdnaTest分析的，接受甲氨蝶呤，长春碱，阿霉素和顺铂（MVAC）一线化疗（CT）一线治疗转移性尿路上皮癌（UC）的患者（pts）早期循环肿瘤细胞（CTC）变化的临床意义
2. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European [J] . Sternberg CN, de-Mulder PH, Schornagel JH, Journal of Clinical Oncology . 2001,第10期

机译：高剂量强度甲氨蝶呤，长春碱，阿霉素和顺铂（MVAC）化疗和重组人粒细胞集落刺激因子与经典MVAC在晚期尿路上皮肿瘤中的随机III期试验：欧洲
3. Possible survival benefit of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin combination therapy (HD-MVAC) over conventional MVAC in metastatic urothelial carcinoma patients. [J] . Inoue T, Obara T, Saito M, 泌尿器科紀要 . 2007,第9期

机译：高剂量甲氨蝶呤，长春碱，阿霉素和顺铂联合疗法（HD-MVAC）较传统MVAC在转移性尿路上皮癌患者中可能具有生存优势。
4. Is High-Dose Chemotherapy Plus Stem-Cell Transplant the Standard Treatment for Patients Failing First-Line Chemotherapy for Metastatic Germ Cell Tumor? [C] . Christian Kollmannsberger, Lawrence Einhorn, Craig Nichols Genitourinary Cancers Symposium. . 2014

机译：高剂量化疗加干细胞移植对转移细胞肿瘤的一线化疗失败的患者的标准治疗吗？
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Clinical Significance of Early Changes in Circulating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma [O] . Emanuela Fina, Andrea Necchi, Patrizia Giannatempo, -1

机译：一线顺铂为基础的转移性尿路上皮癌化疗患者循环肿瘤细胞早期变化的临床意义
7. Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial [O] . Christian Pfister, Valentin Harter, Yves Allory, 2020

机译：随机对照甲尾甲醇三甲产蛋白，长霉素，多柔比星和顺铂（DD-MVAC）或吉西他滨和顺铂（GC）的患者为膀胱局部晚期过渡细胞癌患者的患者的随机致密甲氨蝶呤（DD-MVAC）或吉西他滨和顺铂（GC）的设计。法国Getug / AFU V05 Vesper试用

Clinical significance of early circulating tumor cells (CTC) changes, analyzed by AdnaTest, in patients (pts) receiving first-line methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy (CT) for metastatic urothelial cancer (UC)

著录项

相似文献

相关主题

期刊订阅